JCO- Precision Oncology

JCO PO is a peer-reviewed, online journal that focuses exclusively on publishing articles that contribute to the field of precision oncology. It showcases original research, reports, opinions, and reviews aimed at enhancing the understanding and application of genomics in cancer care. The journal features innovative and relevant scientific content that sheds light on actionable cancer genomics, personalized translational research, and the latest advancements in treatment based on tumor molecular profiling. It encompasses a wide range of clinical research, including basket trials, notable response cases, informatics, and evidence-based case reports that offer educational insights. Additionally, JCO PO includes detailed expert commentary, editorials, and reviews that discuss the complexities and benefits of targeted therapies derived from genomic data. This journal is published by the American Society of Clinical Oncology (ASCO).

National

English

Journal

Outlet metrics

Domain Authority

Ranking

Global

#65265

United States

#29553

Health/Health

#679

Traffic sources

Monthly visitors

Articles

Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies

2 weeks ago | ascopubs.org | Joseph M. Unger |Hillary Andrews |Laura A. Levit

1-3 Given the challenges of recruiting patients to clinical trials during a pandemic, major federal agencies shared guidance to allow more flexibility in trial processes, supporting the continuity of clinical trials while ensuring patient safety and data integrity.4,5 Trial sponsors rapidly adopted these measures, including strategies such as remote patient consent to participate, remote symptom monitoring, and distribution of oral anticancer agents directly to trial patients.4-6 Enrollment...
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches

1 month ago | ascopubs.org | Toby Eyre |Anita Kumar |Steven Le Gouill

Mantle cell lymphoma (MCL) represents a relatively uncommon, heterogeneous lymphoma associated with limited overall survival. Targeting of the B-cell receptor pathway in relapsed disease with covalent Bruton tyrosine kinase (cBTK) inhibition has been demonstrated to be highly effective with cBTK inhibitor monotherapy, an established standard of care in relapsed MCL.
Writing a Medical Memoir: Lessons From a Long, Steep Road

2 months ago | ascopubs.org | Mikkael A. Sekeres

The purpose of this essay is to take hematologist/oncologist readers of the Journal on my challenging journey of trying to write a memoir describing my patients and career. This piece is not just for those who might wish to write a book, it also can be generalized to other creative writing such as short stories or other narrative pieces intended for publication.
SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma | JCO Oncology Advances

2 months ago | ascopubs.org | Adam Olszewski |Michael LeBlanc |Michael Leblanc |Jonathan W. Friedberg

The following protocol information is provided solely to describe how the authors conducted the research underlying this article. The information provided may not reflect the complete protocol or any previous amendments or modifications. As described in the Information for Contributors, JCO OA requests only specific elements of the most recent version of the protocol.
The Evolution of the ASCO Educational Book and the Issues Shaping the Future of Oncology

2 months ago | ascopubs.org | Nate Pennell |Don S. Dizon

On the inaugural episode of ASCO Education: By the Book, Dr. Nathan Pennell and Dr. Don Dizon share reflections on the evolution of the ASCO Educational Book, its global reach, and the role of its new companion podcast to further shine a spotlight on the issues shaping the future of modern oncology. TRANSCRIPTDr. Nathan Pennell:Hello, I'm Dr. Nate Pennell, welcoming you to the first episode of our new podcast,ASCO Education: By the Book.
Tamales: Celebrating a Mexican Christmas Tradition

2 months ago | ascopubs.org | Mikkael A. Sekeres |Megan M. Dupuis

Narrator: Tamales, by Megan Dupuis, MD, PhDI do not know if you know this, but tamales are an important—nay, critical—part of the MexicanChristmas tradition. Before I moved to Texas, I certainly did not know that. I did not know that the simple tamal, made of masa flour and fillings and steamed in a corn husk, is as essential to the holiday season as music and lights. Whole think pieces have been written in The Atlantic about it, for God’s sake. But, I did not know that.
Host Transition: Meet Cancer Stories New Host Dr. Mikkael Sekeres

Jan 14, 2025 | ascopubs.org | Lidia Schapira |Mikkael A. Sekeres

Dr. Lidia Schapira: Hello and welcome to JCO's Cancer Stories: The Art of Oncology, which features essays and personal reflections from authors exploring their experience in the field of oncology. I'm your host, Dr. Lidia Schapira, a Professor of Medicine at Stanford University, and with me today is Dr. Mikkael Sekeres, who is a Professor of Medicine and the Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center in Miami.
Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings From the Friends' HRD Harmonization Project | JCO Oncology Advances

Nov 4, 2024 | ascopubs.org | Hillary Andrews |Lisa M. McShane |Elise C. Kohn

1-3 Patients with high-grade serous ovarian cancer (HGSOC) whose tumors are HRD have better outcomes when treated with PARPi maintenance therapy.4-7 Nearly half of patients with HGSOC have HRD, and approximately half of patients with HRD or about 20% of all patients with HGSOC have a deleterious or potentially deleterious mutation in BRCA1 or BRCA2 (BRCA1/2),7-10 which are integral to the homologous recombination repair (HRR) pathway.
Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy

Oct 1, 2024 | ascopubs.org | Sarah Ferguson |Lori Brotto |Janice Kwon

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center
Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma

Sep 30, 2024 | ascopubs.org | Julia Mattlener |Sophia Sobesky |Janine Altmüller

Authors retain all rights in any data supplements associated with their articlesThe ideas and opinions expressed in these Data Supplements do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in these Data Supplements should not be construed as an endorsement of the products mentioned.